Biohaven (BHVN) highlighted the success of BHV ... In the four-week Phase 1 study, subcutaneously administered BHV-1300 at a dose of 1000 mg weekly achieved rapid, deep and sustained reductions ...

Identifying viruses associated with red tide can help researchers forecast the development of blooms and better understand environmental factors that can cause blooms to terminate. The study marks an ...

Joseph Borzelleca published a study on the food coloring Red No. 3. The FDA cited his work when banning the additive in ...

A study in Bengal Medical Journal reveals alarming antibiotic misuse among footballers in eastern India, with high-risk antibiotics often used without prescriptions. Experts warn this risky ...

A new study claims that a mineral found in Mars' dust called ferrihydrite, which forms in the presence of cool water, is likely what gives the planet its reddish hue.

Dose escalation with BHV-1300 continues in the study and plans to explore deeper reductions to characterize the potential range of targeted IgG lowering possible with Biohaven's MoDE™ technology ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

In addition to focal epilepsy, Biohaven initiated a Phase 2/3 study in generalized epilepsy with the primary efficacy endpoint of the study being time to second day with generalized tonic-clonic ...

Swiss National Bank raised its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 12.2% during the 4th quarter, Holdings Channel reports.The institutional investor owned 154,800 ...

Biohaven completed interactions with FDA enabling registrational programs for Parkinson's disease and the prevention of ARIA. Initiate BHV-8000 Phase 2/3 study in Parkinson's disease in 1H 2025.

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new ... lowering and Phase 1 study completion expected ...